search
Back to results

Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia (EXCEED)

Primary Purpose

Chronic Sinusitis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Propel Nova Sinus Implant
Sponsored by
Intersect ENT
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Chronic Sinusitis focused on measuring Chronic Sinusitis, Endoscopic Sinus Surgery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient is ≥ 18 years of age.
  • Patient is willing and able to comply with protocol requirements.
  • Patient has CS as confirmed by CT scan and defined as symptoms lasting longer than 8 consecutive weeks in duration with inflammation of the mucosa of the nose and paranasal sinuses.
  • Patient's condition and the planned intervention will involve at least two and a maximum of four peripheral sinuses (frontal or maxillary sinuses or combination of both).
  • Patient is a candidate for a planned intervention involving sinus surgery in the operating room or office setting.
  • Patient has nasal polyps no greater than grade 2.
  • Patient with nasal polyps greater than 2 are eligible after their reduction/removal during ESS without significant complications that would confound the study results and leaving the patient's anatomy amenable to sinus implant placement, as judged by the operating physician.
  • Female patients of child-bearing potential must not be pregnant and must agree to not become pregnant during the course of the study.
  • Female patients of child-bearing potential must agree to use consistent and acceptable method/s of birth control during the course of the study.
  • CS diagnosis confirmed and documented by CT Scan within 6 months of the procedure.
  • Patient has a minimum total CT stage (Lund-Mackay method) of 6.
  • Patient has disease in frontal and/or maxillary sinuses confirmed by CT scan.
  • Planned ESS includes bilateral ethmoidectomy (if judged necessary), frontal sinus surgery using Draf II (A or B) dissection and/or balloon dilation, with minimum of 5-mm diameter opening created. In the case of maxillary sinus surgery, traditional antrostomy or balloon dilation, with or without removal of uncinate process, should be performed with minimum of 5-mm diameter opening created.
  • Technique used for frontal or maxillary sinus surgery was the same on both sides (e.g. surgical dissection alone bilaterally, balloon dilation alone bilaterally, or both bilaterally)
  • Septoplasty for access to the ostio-meatal complex is permitted.

Exclusion Criteria:

  • Patient has presence of grade 3 or 4 polyposis, unless removed during surgery and preceding implant placement.
  • Patient has presence of adhesions/scarring grades 3 or 4, unless removed during surgery and preceding implant placement.
  • Patient has known history of immune deficiency (e.g., IGG subclass deficiency or IGA deficiency, HIV).
  • Patient has concurrent condition requiring active chemotherapy and/or immunotherapy management for the disease (e.g., cancer, HIV, etc.).
  • Patient has oral-steroid dependent condition such as COPD, asthma or other condition.
  • Patient has known history of allergy or intolerance to corticosteroids or mometasone furoate.
  • Patient has clinical evidence of acute bacterial sinusitis (e.g. acute increase in purulent discharge, fever, facial pain etc.).
  • Patient has clinical evidence or suspicion of invasive fungal sinusitis (e.g. bone erosion on prior CT scan, necrotic sinus tissue, etc.).
  • Patient has evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments during the 90-day period.
  • Patient is currently participating in another clinical trial.
  • Patient has history of insulin dependent diabetes mellitus.
  • Patient has previously undergone ESS and experienced a CSF leak or has residual compromised vision as a result of a complication in a prior ESS procedure.
  • Patient has known dehiscence of the lamina papyracea.
  • Patient has evidence of active viral illness (e.g., tuberculosis, ocular herpes simplex, chickenpox or measles).
  • Significant complication during the current peripheral ostia surgery/such as excessive blood loss, CSF leak or punctured lamina papyracea.
  • Current surgical intervention (operating room or office setting) is aborted for any reason.

Sites / Locations

  • South Florida ENT Associates
  • Ohio Sinus Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Propel Nova Sinus Implant

Arm Description

Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days

Outcomes

Primary Outcome Measures

Device Placement Success Rate
Defined as successful access to and placement of the Propel Nova Sinus Implant in the frontal or maxillary sinus ostium within two attempts. Calculated as a proportion where the numerator is the number of successful device placements and the denominator is the number of attempted sinuses.

Secondary Outcome Measures

Ostial Patency
Ostial patency grading scale from 0 (patent) to 1 (Occluded/Restenosed)
Adhesion/Scarring Grade 2 & 3
Adhesion/scarring grading scale from 0 (No visible granulation/scarring), 1 (Minimal amount of scarring/contraction observed but non-obstructing the frontal or maxillary sinus ostium), 2 (moderate amount of obstructive scar tissue/contraction present in the frontal or maxillary sinus ostium), 3 (Significant scar tissue/ contraction causing obstruction of the frontal or maxillary sinus ostium)
Degree of Inflammation
Inflammation visual analog scale (VAS) from 0 (no visible inflammation) to 100 (severe inflammation, involving significant and extensive erythema and edema and/or hypertrophy and/or polypoid changes)
Sino-Nasal Outcome Test (SNOT) 22
Validated, disease-specific, symptom-scoring instrument consisting of 22 questions, each scored by the patient on a scale of 0 (no problem) to 5 (problem as bad as it can be), resulting in a maximum total score of 110

Full Information

First Posted
June 25, 2014
Last Updated
April 25, 2017
Sponsor
Intersect ENT
search

1. Study Identification

Unique Protocol Identification Number
NCT02228720
Brief Title
Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia
Acronym
EXCEED
Official Title
The EXCEED Study: A Clinical Evaluation of the Drug-Eluting Propel Nova Sinus Implant When Placed in Peripheral Sinus Ostia to Maintain Patency
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
January 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Intersect ENT

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a feasibility study is to assess the performance, safety and initial signals of efficacy of the drug-eluting Propel Nova Sinus Implant when used in chronic sinusitis patients undergoing sinus surgery of peripheral sinus ostia.
Detailed Description
This is a prospective, single-center, single-arm, open label feasibility study aiming to enroll at least 10 patients and a maximum of 15 patients to achieve 30 treated sinuses. The objective of this feasibility study is to assess the performance, safety and initial signals of efficacy of the drug-eluting Propel Nova Sinus Implant when used in chronic sinusitis (CS) patients undergoing sinus surgery of peripheral sinus ostia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Sinusitis
Keywords
Chronic Sinusitis, Endoscopic Sinus Surgery

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Propel Nova Sinus Implant
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Propel Nova Sinus Implant
Arm Type
Experimental
Arm Description
Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
Intervention Type
Device
Intervention Name(s)
Propel Nova Sinus Implant
Other Intervention Name(s)
Propel Contour Sinus Implant (mometasone furoate, 370 mcg)
Intervention Description
Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
Primary Outcome Measure Information:
Title
Device Placement Success Rate
Description
Defined as successful access to and placement of the Propel Nova Sinus Implant in the frontal or maxillary sinus ostium within two attempts. Calculated as a proportion where the numerator is the number of successful device placements and the denominator is the number of attempted sinuses.
Time Frame
Baseline Procedure
Secondary Outcome Measure Information:
Title
Ostial Patency
Description
Ostial patency grading scale from 0 (patent) to 1 (Occluded/Restenosed)
Time Frame
Baseline, Day 30, Day 90
Title
Adhesion/Scarring Grade 2 & 3
Description
Adhesion/scarring grading scale from 0 (No visible granulation/scarring), 1 (Minimal amount of scarring/contraction observed but non-obstructing the frontal or maxillary sinus ostium), 2 (moderate amount of obstructive scar tissue/contraction present in the frontal or maxillary sinus ostium), 3 (Significant scar tissue/ contraction causing obstruction of the frontal or maxillary sinus ostium)
Time Frame
Baseline, Day 30, Day 90
Title
Degree of Inflammation
Description
Inflammation visual analog scale (VAS) from 0 (no visible inflammation) to 100 (severe inflammation, involving significant and extensive erythema and edema and/or hypertrophy and/or polypoid changes)
Time Frame
Baseline, Day 30, Day 90
Title
Sino-Nasal Outcome Test (SNOT) 22
Description
Validated, disease-specific, symptom-scoring instrument consisting of 22 questions, each scored by the patient on a scale of 0 (no problem) to 5 (problem as bad as it can be), resulting in a maximum total score of 110
Time Frame
Baseline, Day 30, Day 90

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is ≥ 18 years of age. Patient is willing and able to comply with protocol requirements. Patient has CS as confirmed by CT scan and defined as symptoms lasting longer than 8 consecutive weeks in duration with inflammation of the mucosa of the nose and paranasal sinuses. Patient's condition and the planned intervention will involve at least two and a maximum of four peripheral sinuses (frontal or maxillary sinuses or combination of both). Patient is a candidate for a planned intervention involving sinus surgery in the operating room or office setting. Patient has nasal polyps no greater than grade 2. Patient with nasal polyps greater than 2 are eligible after their reduction/removal during ESS without significant complications that would confound the study results and leaving the patient's anatomy amenable to sinus implant placement, as judged by the operating physician. Female patients of child-bearing potential must not be pregnant and must agree to not become pregnant during the course of the study. Female patients of child-bearing potential must agree to use consistent and acceptable method/s of birth control during the course of the study. CS diagnosis confirmed and documented by CT Scan within 6 months of the procedure. Patient has a minimum total CT stage (Lund-Mackay method) of 6. Patient has disease in frontal and/or maxillary sinuses confirmed by CT scan. Planned ESS includes bilateral ethmoidectomy (if judged necessary), frontal sinus surgery using Draf II (A or B) dissection and/or balloon dilation, with minimum of 5-mm diameter opening created. In the case of maxillary sinus surgery, traditional antrostomy or balloon dilation, with or without removal of uncinate process, should be performed with minimum of 5-mm diameter opening created. Technique used for frontal or maxillary sinus surgery was the same on both sides (e.g. surgical dissection alone bilaterally, balloon dilation alone bilaterally, or both bilaterally) Septoplasty for access to the ostio-meatal complex is permitted. Exclusion Criteria: Patient has presence of grade 3 or 4 polyposis, unless removed during surgery and preceding implant placement. Patient has presence of adhesions/scarring grades 3 or 4, unless removed during surgery and preceding implant placement. Patient has known history of immune deficiency (e.g., IGG subclass deficiency or IGA deficiency, HIV). Patient has concurrent condition requiring active chemotherapy and/or immunotherapy management for the disease (e.g., cancer, HIV, etc.). Patient has oral-steroid dependent condition such as COPD, asthma or other condition. Patient has known history of allergy or intolerance to corticosteroids or mometasone furoate. Patient has clinical evidence of acute bacterial sinusitis (e.g. acute increase in purulent discharge, fever, facial pain etc.). Patient has clinical evidence or suspicion of invasive fungal sinusitis (e.g. bone erosion on prior CT scan, necrotic sinus tissue, etc.). Patient has evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments during the 90-day period. Patient is currently participating in another clinical trial. Patient has history of insulin dependent diabetes mellitus. Patient has previously undergone ESS and experienced a CSF leak or has residual compromised vision as a result of a complication in a prior ESS procedure. Patient has known dehiscence of the lamina papyracea. Patient has evidence of active viral illness (e.g., tuberculosis, ocular herpes simplex, chickenpox or measles). Significant complication during the current peripheral ostia surgery/such as excessive blood loss, CSF leak or punctured lamina papyracea. Current surgical intervention (operating room or office setting) is aborted for any reason.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William J. Brown, MD
Organizational Affiliation
South Florida ENT Associates, PA
Official's Role
Principal Investigator
Facility Information:
Facility Name
South Florida ENT Associates
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Ohio Sinus Institute
City
Dublin
State/Province
Ohio
ZIP/Postal Code
43016
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia

We'll reach out to this number within 24 hrs